Findings published in the journal Pharmacopsychiatry, based on an online survey conducted in Germany between June 2020 and August 2020 with more than 1,000 patients, debunked the claim that high-THC cannabis poses unique health risks.

“Patients were allowed to participate only if they received a cannabis-based treatment from pharmacies in the form of cannabis flowers prescribed by a physician,” the researchers explained. 

“Overall, the mean patient-reported effectiveness was 80.1% (range, 0–100%). A regression model revealed no association between the patient-reported effectiveness and the variety. Furthermore, no influence of the disease on the choice of the [medical cannabis] strain was detected. On average, 2.1 side effects were reported (most commonly dry mouth (19.5%), increased appetite (17.1%), and tiredness (13.0%)). However, 29% of participants did not report any side effects. Only 398 participants (38.7%) indicated that costs for [medical cannabis] were covered by their health insurance,” they continued. 

The researchers said that patients “self-reported very good efficacy and tolerability” of medical cannabis, and that there “was no evidence suggesting that specific [medical cannabis] strains are superior depending on the disease to be treated.”

The findings are notable given that in Europe “pharmaceutical-grade cannabis flower…contain THC levels of 20 percent or greater,” according to NORML.

NORML said that the survey’s findings “push back against claims that cannabis strains higher in THC pose unique risks to health or that there is an absence of research supporting the efficacy of medical cannabis chemovars above 10 percent THC.”

The researchers behind the survey said that they were driven to examine the matter due to the lack of research containing high-potency medical cannabis. Their findings, they said, represent “the first large study exploring the effectiveness and tolerability of different cannabis strains prescribed by physicians in Germany.”

“There is increasing evidence that cannabis-based medicine (CBM) is efficacious in many different indications, mainly chronic pain, spasticity in multiple sclerosis, and palliative care. After reintroduction in medicine, the number and type of available CBM constantly increased, ranging from pure tetrahydrocannabinol (THC) to pure cannabidiol (CBD), as well as cannabis extracts and flowers with very different THC:CBD ratios. In Germany, cannabis flowers and extracts were legalized for medical purposes in 2017. In limited exceptional cases and after approval (according to the Social Insurance Code), costs are covered by health insurance. Today (as of 2023), in Germany, more than 150 different cannabis flowers can be prescribed. However, it is largely unknown, whether particular strains and/or different concentrations of THC, CBD, other cannabinoids, and further ingredients, including terpenes and flavonoids, result in different effectiveness in different conditions,” they said.

“So far, only a limited number of studies directly compared the effects of different cannabis strains in different indications. According to data collected between 2009 and 2010 from 600 patients registered with the Vancouver Island Compassion Society and treated with medicinal cannabis (MC), the ‘more popular’ Cannabis indica strains more effectively relieved pain compared to C. sativa strains. Several characteristics were found to be similar for both species, e. g., trust in purity, route of administration, and reason for use (recreational vs. medicinal).”

Still, the researchers also noted limits to their findings, and cautioned against drawing too many sweeping conclusions.

“We failed to confirm our main hypothesis that specific cannabis strains are more efficacious in specific indications. There was also no influence of the respective indication on the choice of the MC strain,” they said. “Besides one strain, all strains preferred by participants were THC dominant with high THC concentrations. Self-reported effectiveness and tolerability of MC for the treatment of a variety of medical conditions were rated as excellent, with no relevant differences between C. sativa, indica, or hybrid. The majority of patients had used cannabis as a self-medication as well as MC prescribed by physicians for years. The overall profile of smell and taste was rated as very good. On the other hand, average cost-effectiveness was rated as poor, which is probably because the majority of patients did not get cost coverage from their health insurance.”

Other limitations include of the study include “(i) only German-speaking patients could be included, (ii) most participants came from Germany, and thus data represent only a small geographical region, (iii) only data for MC strains available in German pharmacies in 2020 could be collected; (iv) data were collected online based on self-reported diagnoses and treatment effects, (v) it cannot entirely be excluded that participants provided untruthful information.” 

But the study also “has several strengths,” they said, noting its “large sample size…relatively short recruitment time…inclusion of only patients that used MC from pharmacies prescribed by physicians…patients with a wide spectrum of different indications…relatively long time use of MC…and use of 5.9 different MC strains on average allowing comparison with respect to clinical effectiveness.” 

The post Survey: High-THC Flower Yields Few Serious Side Effects in Patients first appeared on High Times.

The post Survey: High-THC Flower Yields Few Serious Side Effects in Patients appeared first on Paradise Found.

In 1996, California was the first state to legalize medical marijuana. Following this, 40 states along with the District of Columbia have legalized the medical application of cannabis. Additionally, the District of Columbia and 24 states have allowed cannabis for recreational or adult-use (although four have yet to launch their commercial retail markets). In all of these instances, as with alcohol, the age allowed to use cannabis is 21. But in Washington, there’s a bill that specifically proposes raising the minimum legal sale age for cannabis products with more than 35% THC concentration to 25 years, with an exemption for qualified patients and designated medical providers.

House Bill 2320, addressing “high-THC cannabis products,” was introduced in the Washington state House Committee on Regulated Substances and Gaming by Representatives Lauren Davis, D-Shoreline, and Tom Dent, R-Moses Lake, on January 11, with a public hearing on January 16. They argue that high-THC cannabis products present both physical and mental risks that need to be addressed.

“Today, there’s no legal limit on the potency of the psychoactive element, THC, in cannabis concentrates,” Davis said. “Cannabis vape oils, dabs, and shatter are regularly sold with a THC potency of nearly 100 percent—a ten-fold increase in potency from when cannabis was legalized in 2012. These concentrated products are different. And dangerous,” KOIN 06 reports.

“The cannabis industry has changed considerably since cannabis was legalized,” Dent said. “This legislation is needed to address the everchanging market and put some measures in place to protect cannabis users and our youth.”

As Cannabis Business Times reports, back in November of 2012 Washington, along with Colorado, became the inaugural states to legalize cannabis for adult use. Starting in 2014, both states initiated sales of adult-use cannabis for individuals aged 21 and over. Since then, an additional 18 states have adopted similar legislation. But if the bill passes, that age will rise to 25. Numerous advocates for legalization in the U.S. argue that the age limit for cannabis sales should align with that of alcohol sales. However, legislators in various state governments, holding more conservative views, have advocated raising the cannabis age limit to 25 years. They justify this by citing that human brain development continues up to that age. 

While the brain ceases growing in size by your early teens, it doesn’t complete its development and maturation until the mid-to-late 20s. The prefrontal cortex (located behind the forehead) is among the last regions to fully mature. It plays a key role in abilities such as planning, prioritizing, and decision-making. There is some evidence that cannabis can alter the teenage brain, and that one should wait until adulthood to enjoy the substance. However, simply looking at human nature, or how little current prohibition—or to compare, even the drinking age—actually halts consumption, the bill aimed at raising the age of allowed cannabis use from 21 to 25 is somewhat absurd because it won’t change a damn thing other than further stifle legal markets. 

The bill’s sponsors argue that their reasoning is backed by the work of scientists from Washington State University and the University of Washington, based on a November 2020 report on “Cannabis Concentration and Health Risks.”

The paper states that: “Use of cannabis with high THC concentration increases the chances of developing cannabis use disorder or addiction to cannabis, particularly among adolescents,” according to the university researchers. “Daily cannabis use, particularly of high potency products, increases the risk of developing a psychotic disorder, like schizophrenia, and is related to an earlier onset of symptoms compared to people who do not use cannabis.”

While such language is included in the bill, David and Dent kept out the part that such evidence is talking about the effects of THC on those between the ages of 14 and 19, not 21 to 25, the age of adults that would be affected by the bill if it passes. 

The bill would also require Washington’s Department of Health to create voluntary training programs for retail cannabis staff on potential health and safety affects and requires the University of Washington’s Addictions, Drug & Alcohol Institute (ADAI) to put into effect guidelines for healthcare providers and patients deemed “at risk of severe complications from cannabis use.” 

Another day, another expensive, red-taped-riddled waste of taxpayer money created by fudging with science that could otherwise be useful. 

The post Proposal in Washington Seeks to Raise Legal Cannabis Age to 25 appeared first on High Times.

The post Proposal in Washington Seeks to Raise Legal Cannabis Age to 25 appeared first on Paradise Found.